Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Model 20066 Left Ventricular (LV) Lead Study

This study has been completed.
Information provided by (Responsible Party):
Medtronic Cardiac Rhythm and Heart Failure Identifier:
First received: May 25, 2011
Last updated: October 10, 2016
Last verified: October 2016
Heart failure is a progressive disease that decreases the pumping action of the heart. This may cause a backup of fluid in the heart and may result in heart beat changes. When there are changes in the heart beat sometimes an implantable heart device is used to control the rate and rhythm of the heart beat. In certain heart failure cases, when the two lower chambers of the heart no longer beat in a coordinated manner, cardiac resynchronization therapy (CRT) may be prescribed. CRT is similar to a pacemaker. It is placed (implanted) under the skin of the upper chest. CRT is delivered as tiny electrical pulses to the right and left ventricles through three leads (flexible insulated wires) that are inserted through the veins to the heart. The purpose of this study is to evaluate a new lead for delivering energy to the left ventricle (bottom left chamber of the heart).

Condition Intervention Phase
Heart Failure
Device: Pacing Lead
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Model 20066 Left Ventricular (LV) Lead Study

Resource links provided by NLM:

Further study details as provided by Medtronic Cardiac Rhythm and Heart Failure:

Primary Outcome Measures:
  • Number of implant procedure related and lead-related complications in the first month post-implant [ Time Frame: One Month ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Success rate of the Model 20066 lead [ Time Frame: Within 24 hours of procedure initiation ] [ Designated as safety issue: No ]
  • Cannulation time [ Time Frame: Within 24 hours of procedure initiation ] [ Designated as safety issue: No ]
  • Fluoroscopy Time [ Time Frame: Within 24 hours of procedure initiation ] [ Designated as safety issue: No ]
  • Model 20066 Lead Placement Time [ Time Frame: Within 24 hours of procedure initiation ] [ Designated as safety issue: No ]
  • Total Implant Time [ Time Frame: Within 24 hours of procedure initiation ] [ Designated as safety issue: No ]
  • Assessment of Lead Handling Characteristics [ Time Frame: Within 24 hours of procedure initiation ] [ Designated as safety issue: No ]
  • Electrical Performance-Tip Electrode: LV Voltage Threshold [ Time Frame: 12-month ] [ Designated as safety issue: No ]
  • Electrical Performance -Tip Electrode: Sensing [ Time Frame: 12-month ] [ Designated as safety issue: No ]
  • Electrical Performance -Tip Electrode: Pacing Impedance [ Time Frame: 12-month ] [ Designated as safety issue: No ]
  • Electrical Performance -Ring Electrode: LV Voltage Threshold [ Time Frame: 12-month ] [ Designated as safety issue: No ]
  • Electrical Performance -Ring Electrode: Sensing [ Time Frame: Within 24 hours of procedure initiation ] [ Designated as safety issue: No ]
  • Electrical Performance -Ring Electrode: Pacing Impedance [ Time Frame: 12-month ] [ Designated as safety issue: No ]
  • Summarize All Adverse Events [ Time Frame: 12-month ] [ Designated as safety issue: No ]
  • Summarize Final 20066 Lead Position [ Time Frame: Within 24 hours of procedure initiation ] [ Designated as safety issue: No ]

Enrollment: 40
Study Start Date: July 2011
Study Completion Date: December 2015
Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 20066 Lead
Non-randomized study. Intervention: Device: Pacing Lead
Device: Pacing Lead
Implant and follow up of Model 20066 lead


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient meets CRT inclusion criteria as determined by local regulatory and/or hospital policy
  • Patient has signed and dated the study-specific informed consent form
  • Patient is 18 years of age or older
  • Patient is expected to remain available for follow-ups at the investigational center
  • Patient is willing and able to comply with protocol

Exclusion Criteria:

  • Patient has a previous complete atrial based biventricular CRT system
  • Patient has a previous LV lead implanted or previous implant attempt within 30 days of implant or ongoing Adverse Events from previous unsuccessful attempt
  • Patient has known coronary venous vasculature that is inadequate for lead placement
  • Patient has unstable angina pectoris or has had an acute myocardial infarction (MI) within the past month
  • Patient has had a coronary artery bypass graft (CABG) or percutaneous transluminal coronary angioplasty (PTCA) within the past three months
  • Patient has chronic (permanent) atrial arrhythmias
  • Patient has contraindications for standard transvenous cardiac pacing (e.g., mechanical right heart valve)
  • Patient has had a heart transplant (patients waiting for heart transplants are allowed in the study)
  • Patient is enrolled in any concurrent drug and/or device study that may confound the results of this study
  • Patient has a terminal illness and is not expected to survive more than three months
  • Patient meets exclusion criteria required by local law (e.g. age, incompetence, pregnancy, breast feeding, etc).
  • Patient is unable to tolerate an urgent thoracotomy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01365234

London, Canada
Newmarket, Canada
Kuala Lumpur, Malaysia
Stockholm, Sweden
Sponsors and Collaborators
Medtronic Cardiac Rhythm and Heart Failure
Principal Investigator: Raymond Yee, MD London Health Sciences Centre, London, Ontario, Canada
  More Information

Responsible Party: Medtronic Cardiac Rhythm and Heart Failure Identifier: NCT01365234     History of Changes
Other Study ID Numbers: Model 20066 
Study First Received: May 25, 2011
Last Updated: October 10, 2016
Health Authority: Canada: Health Canada
Sweden: Regional Ethical Review Board
Malaysia: Ministry of Health
Individual Participant Data  
Plan to Share IPD: Undecided

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases processed this record on October 25, 2016